细胞色素P4502D6遗传多态性与帕罗西汀临床效应的相关性研究

The Relationship Between the Polymorphism of Cytochrome P4502D6 and Clinical Response of Paroxetine

目的：研究中国人细胞色素Ｐ４ ５０２Ｄ６（ＣＹＰ２Ｄ６）Ａ、Ｂ及Ｃｈ进行基因突变分析与帕罗西汀临床效应之间的关系。方法：采用ＰＣＲ－ＲＦＬＰ法对８５例抑郁症患者进行基因型分析，并分组用 ＨＡＭＤ和 ＴＥＳＳ评定患者治疗前，治疗 ４周和 ８周后的抑郁状态及药物不良反应，比较各基因型组患者采用帕罗西汀治疗的疗效和药物不良反应。结果：（１）ＣＹＰ２Ｄ６等位基因频率分别为：Ｗｔ（４９．５％），Ｃｈ（５０．０％），Ｂ（０．５％）。未检出Ａ等位基因。（２）不同基因型组患者治疗后ＨＡＭＤ评分显著降低；不同基因型患者之间治疗前 ＨＡＭＤ评分、治疗４周和 ８周后ＨＡＭＤ评分及减分率，以及ＴＥＳＳ评分之间的差异均无显著性意义；患者治疗前ＨＡＭＤ评分、治疗后ＨＡＭＤ评分及减分率、ＴＥＳＳ评分等均与年龄、性别、病程、ＣＹＰ２Ｄ６基因型、突变等位基因数目之间的相关性无显著性意义。结论：本研究未发现抑郁症患者ＣＹＰＺＤ６基因多态性与帕罗西汀临床效应之间存在相关性。

OBJECTIVE: To study the relationship between gene analysis of CYP2D6 A. B and Ch in Chinese subjects with the clinical effectiveness of paroxetine. METHODS: 85 patients with major depression carried out gene analysis by PCR- RFLP. The groups of patients were assessed with depressive states , drug adverse reaction preceding treatment, for 4 weeks and 8 weeks using HAMD and TESS. Compare the effectiveness of paroxetine and drug adverse reaction with groups of genotype.RESULTS: (1 )the allelic frequencies were:wt(49.5%),Ch(50.O%)and(O.5%) respectively.The allele A was unable to be detected. (2)the post-treated HAMD of all the patients decreased significantly. But there were no significant differences in pre-and post-treated HAMD scores, the reductive ratio of HAMD scores, and the TESS scores in patients with different CYP2D6 genotype. The pre-and post-treated HAMD scores, the reductive ratio of HAMD scores, and the TESS scores showed no significant corelationships with age, sex, duration of illness, CYP2D6 genotype, and the number of mutant alleles. CONCLUSION: The association genetic polymorphism CYP2D6 with the clinical effects of paroxetine were not found.